Moderna’s combined Covid-19 and flu vaccine matched the efficacy of single shots in late-stage trial results published on Monday, opening the door for the mRNA vaccine maker to seek approval for its third product.
周一公布的后期試驗結果顯示,莫德納(Moderna)的新冠和流感聯合疫苗與單獨疫苗的效力相當,這意味著這家mRNA疫苗生產商能夠為其第三款產品申請許可。
您已閱讀6%(289字),剩余94%(4545字)包含更多重要信息,訂閱以繼續探索完整內容,并享受更多專屬服務。